首页 > 最新文献

Zeitschrift fur Rheumatologie最新文献

英文 中文
[Is lymphoma screening necessary in Sjögren`s disease, and if so, how?] [是否有必要对斯约格伦病患者进行淋巴瘤筛查,如果有必要,如何筛查?]
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-12 DOI: 10.1007/s00393-024-01562-3
Torsten Witte
{"title":"[Is lymphoma screening necessary in Sjögren`s disease, and if so, how?]","authors":"Torsten Witte","doi":"10.1007/s00393-024-01562-3","DOIUrl":"https://doi.org/10.1007/s00393-024-01562-3","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Digital health applications-What we should know as rheumatologists]. [数字医疗应用--作为风湿病学家我们应该知道什么]。
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-10 DOI: 10.1007/s00393-024-01570-3
Johannes Knitza, Martin Krusche, Gamal Chehab, Christof Specker, Jutta G Richter

Digital health applications (DHAs) are revolutionising patient care by improving access to evidence-based therapy and promoting active self-management. The continuously growing number of DHAs enables patients to act more independently through digital support. The budget-neutral prescription and cost coverage by statutory health insurance companies reduce financial barriers for practitioners and patients. Initial studies show that DHAs can be used successfully to treat comorbidities and rheumatic diseases. Several DHAs for inflammatory rheumatic diseases are at an advanced stage of development. The identification of suitable patients and support through shared decision making are crucial for successful implementation. Challenges remain in adherence and acceptance of the applications. This article provides an overview of prescription in clinical routine, initial data and experiences from the reality of rheumatology care, and reports on current developments.

数字医疗应用程序(DHA)通过改善循证治疗的获取途径和促进积极的自我管理,正在彻底改变患者护理。数字健康应用程序的数量不断增加,使患者能够通过数字支持更加独立地行动。不影响预算的处方和由法定医疗保险公司承担的费用减少了从业人员和患者的经济障碍。初步研究表明,DHA 可成功用于治疗合并症和风湿性疾病。几种治疗炎症性风湿病的 DHA 已进入后期开发阶段。确定合适的患者并通过共同决策提供支持是成功实施的关键。在应用的依从性和接受度方面仍存在挑战。本文概述了临床常规处方、风湿病护理现实中的初步数据和经验,并报告了当前的发展情况。
{"title":"[Digital health applications-What we should know as rheumatologists].","authors":"Johannes Knitza, Martin Krusche, Gamal Chehab, Christof Specker, Jutta G Richter","doi":"10.1007/s00393-024-01570-3","DOIUrl":"https://doi.org/10.1007/s00393-024-01570-3","url":null,"abstract":"<p><p>Digital health applications (DHAs) are revolutionising patient care by improving access to evidence-based therapy and promoting active self-management. The continuously growing number of DHAs enables patients to act more independently through digital support. The budget-neutral prescription and cost coverage by statutory health insurance companies reduce financial barriers for practitioners and patients. Initial studies show that DHAs can be used successfully to treat comorbidities and rheumatic diseases. Several DHAs for inflammatory rheumatic diseases are at an advanced stage of development. The identification of suitable patients and support through shared decision making are crucial for successful implementation. Challenges remain in adherence and acceptance of the applications. This article provides an overview of prescription in clinical routine, initial data and experiences from the reality of rheumatology care, and reports on current developments.</p>","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Physical therapy in rheumatology : What, when and how can it be prescribed?] [风湿病学中的物理疗法:该如何使用?]
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-06 DOI: 10.1007/s00393-024-01558-z
Uwe Lange, Antje Dominok

Treatment of a rheumatic diseases without physical and occupational therapy is almost incomplete because it cannot be replaced by anything else; however, slightly less than half of all insured persons with inflammatory rheumatic diseases only receive an outpatient prescription and this proportion has hardly changed in the last 15 years. This is even more surprising as those affected persons often have limitations in functional health due to multimorbidity, which are very accessible by physical measures. The article is intended to serve as a basis for a recourse-proof prescription in order to make even greater use of the corresponding possibilities of an outpatient physical prescription in the future.

没有物理和职业治疗的风湿病治疗几乎是不完整的,因为它无法被其他任何东西所替代;然而,在所有患有炎症性风湿病的投保人中,只有不到一半的人只接受门诊处方治疗,而这一比例在过去 15 年中几乎没有变化。这就更令人吃惊了,因为这些患者往往由于多病而在功能健康方面受到限制,而这些限制通过物理措施是非常容易获得的。这篇文章的目的是为今后更广泛地利用门诊物理处方的相应可能性提供一个可求助的处方基础。
{"title":"[Physical therapy in rheumatology : What, when and how can it be prescribed?]","authors":"Uwe Lange, Antje Dominok","doi":"10.1007/s00393-024-01558-z","DOIUrl":"https://doi.org/10.1007/s00393-024-01558-z","url":null,"abstract":"<p><p>Treatment of a rheumatic diseases without physical and occupational therapy is almost incomplete because it cannot be replaced by anything else; however, slightly less than half of all insured persons with inflammatory rheumatic diseases only receive an outpatient prescription and this proportion has hardly changed in the last 15 years. This is even more surprising as those affected persons often have limitations in functional health due to multimorbidity, which are very accessible by physical measures. The article is intended to serve as a basis for a recourse-proof prescription in order to make even greater use of the corresponding possibilities of an outpatient physical prescription in the future.</p>","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nachruf auf Herrn Professor Dr. sc. med. Wolfgang Keitel. 沃尔夫冈-凯特尔教授的讣告。
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-03 DOI: 10.1007/s00393-024-01561-4
Eugen Feist, Karsten Beyer, Carlo Weimann
{"title":"Nachruf auf Herrn Professor Dr. sc. med. Wolfgang Keitel.","authors":"Eugen Feist, Karsten Beyer, Carlo Weimann","doi":"10.1007/s00393-024-01561-4","DOIUrl":"https://doi.org/10.1007/s00393-024-01561-4","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Procedures of complementary medicine in rheumatology]. [风湿病学中的补充医学程序]。
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-06-27 DOI: 10.1007/s00393-024-01524-9
Gernot Keyßer, Inna Frohne, Olaf Schultz, Monika Reuß-Borst, Oliver Sander, Alexander Pfeil

Patients with diseases of the musculoskeletal system are confronted with a large quantity of treatment offers based on methods of complementary medicine. Despite a considerable number of publications on this topic, the scientific evidence is still poor. This article focuses on Ayurvedic medicine (AM), traditional Chinese medicine (TCM), mind-body medicine and homeopathy. These procedures have a longstanding tradition of practice and each claims to have its own theoretical concept; however, the application in the field of rheumatology can only be recommended either for specific entities or, in the case of homeopathy, not at all. In addition, this article summarizes the evidence for dietary recommendations, nutritional supplements and herbal medicine in rheumatology. The latter topics are frequently discussed in the popular press and are a much-debated issue between physicians and patients; however, clear-cut recommendations for the application on a scientific basis are the exception and mainly consist of the endorsement to adhere to the principles of a Mediterranean diet.

肌肉骨骼系统疾病患者面临着大量基于补充医学方法的治疗方案。尽管有关这一主题的出版物数量可观,但科学证据仍然贫乏。本文重点介绍阿育吠陀医学(AM)、传统中医(TCM)、身心医学和顺势疗法。这些疗法有着悠久的实践传统,每种疗法都声称有自己的理论概念;然而,在风湿病学领域的应用只能针对特定的实体进行推荐,或者就顺势疗法而言,根本无法推荐。此外,本文还总结了风湿病学中饮食建议、营养补充剂和草药的证据。这些话题经常在大众媒体上讨论,也是医生和患者之间争论不休的问题;然而,有科学依据的明确应用建议是个例外,主要包括赞同坚持地中海饮食原则。
{"title":"[Procedures of complementary medicine in rheumatology].","authors":"Gernot Keyßer, Inna Frohne, Olaf Schultz, Monika Reuß-Borst, Oliver Sander, Alexander Pfeil","doi":"10.1007/s00393-024-01524-9","DOIUrl":"10.1007/s00393-024-01524-9","url":null,"abstract":"<p><p>Patients with diseases of the musculoskeletal system are confronted with a large quantity of treatment offers based on methods of complementary medicine. Despite a considerable number of publications on this topic, the scientific evidence is still poor. This article focuses on Ayurvedic medicine (AM), traditional Chinese medicine (TCM), mind-body medicine and homeopathy. These procedures have a longstanding tradition of practice and each claims to have its own theoretical concept; however, the application in the field of rheumatology can only be recommended either for specific entities or, in the case of homeopathy, not at all. In addition, this article summarizes the evidence for dietary recommendations, nutritional supplements and herbal medicine in rheumatology. The latter topics are frequently discussed in the popular press and are a much-debated issue between physicians and patients; however, clear-cut recommendations for the application on a scientific basis are the exception and mainly consist of the endorsement to adhere to the principles of a Mediterranean diet.</p>","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Looking back on 51 years of the Carol Nachman Prize in Rheumatology-significance for the field of spondyloarthritis research. 回顾卡罗尔-纳赫曼风湿病学奖设立51年--对脊柱关节炎研究领域的意义。
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI: 10.1007/s00393-024-01496-w
Jürgen Braun, Joachim Sieper, Elisabeth Märker-Hermann

The city and casino of Wiesbaden, capital of the German state Hessen, have endowed the Carol Nachman Prize to promote research work in the field of rheumatology since 1972. The prize, endowed with 37,500 €, is the second highest medical award in Germany and serves to promote clinical, therapeutic, and experimental research work in the field of rheumatology. In June 2022, the 50-year anniversary was celebrated. In the symposium preceding the award ceremony, an overview was given on the significance of spondyloarthritis for the work of the awardees in the past 30 years. This overview has now been put together to inform the interested community of the work performed, including the opinion of the awardees regarding what they consider to be their most important contribution.

德国黑森州首府威斯巴登市和威斯巴登赌场自 1972 年以来一直为促进风湿病学领域的研究工作而设立卡罗尔-纳赫曼奖。该奖奖金额为 37500 欧元,是德国第二高医学奖,旨在促进风湿病学领域的临床、治疗和实验研究工作。2022 年 6 月,该奖项迎来了 50 周年纪念。在颁奖仪式前的研讨会上,对脊柱关节炎在过去 30 年中对获奖者工作的意义进行了概述。现在,我们将这一概述整理成文,向感兴趣的各界人士介绍已开展的工作,包括获奖者对他们认为自己最重要的贡献的看法。
{"title":"Looking back on 51 years of the Carol Nachman Prize in Rheumatology-significance for the field of spondyloarthritis research.","authors":"Jürgen Braun, Joachim Sieper, Elisabeth Märker-Hermann","doi":"10.1007/s00393-024-01496-w","DOIUrl":"10.1007/s00393-024-01496-w","url":null,"abstract":"<p><p>The city and casino of Wiesbaden, capital of the German state Hessen, have endowed the Carol Nachman Prize to promote research work in the field of rheumatology since 1972. The prize, endowed with 37,500 €, is the second highest medical award in Germany and serves to promote clinical, therapeutic, and experimental research work in the field of rheumatology. In June 2022, the 50-year anniversary was celebrated. In the symposium preceding the award ceremony, an overview was given on the significance of spondyloarthritis for the work of the awardees in the past 30 years. This overview has now been put together to inform the interested community of the work performed, including the opinion of the awardees regarding what they consider to be their most important contribution.</p>","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141306991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Aphthous ulcers in a patient of Turkish descent : A diagnostic challenge]. [土耳其裔患者的阿弗他溃疡:诊断难题]。
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-03-18 DOI: 10.1007/s00393-024-01498-8
Kathrin Standfest, Vanessa Bartsch, Manuela Beckert, Axel J Hueber
{"title":"[Aphthous ulcers in a patient of Turkish descent : A diagnostic challenge].","authors":"Kathrin Standfest, Vanessa Bartsch, Manuela Beckert, Axel J Hueber","doi":"10.1007/s00393-024-01498-8","DOIUrl":"10.1007/s00393-024-01498-8","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anakinra in idiopathic recurrent pericarditis: a comprehensive case series and literature review. 用于特发性复发性心包炎的 Anakinra:综合病例系列和文献综述。
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-01-26 DOI: 10.1007/s00393-023-01471-x
Zeynep Toker Dincer, Sejla Karup, Erkin Yilmaz, Osman Corbali, Feyza Nur Azman, Melike Melikoglu, Serdal Ugurlu

Objective: Idiopathic recurrent pericarditis (IRP) is defined by recurring episodes of pericardial inflammation without a known cause. This study investigates the safety and efficacy of anakinra, an interleukin‑1 inhibitor, as a successful therapy for IRP in cases resistant to conventional treatment.

Methods: A retrospective evaluation of patients treated at our autoinflammatory center between 2011 and 2023 was conducted. Patient files were examined for demographic, clinical, and treatment response data, including nonsteroid anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine. Monogenic autoinflammatory disease screening was performed for Mediterranean Fever (MEFV), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase (MVK), nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3), and nucleotide-binding oligomerization domain-containing protein 2 (NOD2). Patients who experienced multiple episodes of pericarditis were diagnosed with recurrent pericarditis. The study evaluated anakinra treatment in IRP patients unresponsive to conventional therapy.

Results: The study included 21 participants, 9 (42.9%) female and 12 (57.1%) male. The average age of the participants was 43.1 ± 16.5 years. The MEFV mutation analysis revealed that 2 (9.5%) had a mutation in exon 10 and 4 (19.0%) had one in exon 2. Out of the 16 cases, 15 successfully discontinued steroid treatment. Four patients (19.0%) experienced injection site reactions. C‑reactive protein (CRP) levels were measured at an average of 196 ± 67.8 mg/l before and 2.6 ± 3.15 mg/l after anakinra treatment.

Conclusion: In conclusion, the study adds to the growing evidence for the efficacy of interleukin-1 inhibitors, such as anakinra, as a promising treatment modality for IRP in cases resistant to conventional treatment.

目的:特发性复发性心包炎(IRP)是指无明确病因而反复发作的心包炎症。本研究探讨了白细胞介素-1抑制剂阿纳金拉(anakinra)的安全性和有效性,并将其作为一种成功的IRP治疗方法,用于常规治疗无效的病例:方法:对2011年至2023年期间在我院自体免疫炎症中心接受治疗的患者进行回顾性评估。检查了患者档案中的人口统计学、临床和治疗反应数据,包括非甾体抗炎药(NSAIDs)、皮质类固醇激素和秋水仙碱。对地中海热(MEFV)、肿瘤坏死因子受体相关周期性综合征(TRAPS)、甲羟戊酸激酶(MVK)、核苷酸结合域、富含亮氨酸家族、含吡啶结构域-3(NLRP3)和含核苷酸结合寡聚化结构域蛋白 2(NOD2)等单基因自身炎症性疾病进行了筛查。多次发作心包炎的患者被诊断为复发性心包炎。该研究评估了对常规疗法无反应的IRP患者的anakinra治疗效果:研究共纳入 21 名参与者,其中女性 9 人(42.9%),男性 12 人(57.1%)。参与者的平均年龄为(43.1 ± 16.5)岁。MEFV突变分析显示,2例(9.5%)在第10外显子发生突变,4例(19.0%)在第2外显子发生突变。在 16 例患者中,有 15 例成功中止了类固醇治疗。四名患者(19.0%)出现了注射部位反应。经测量,C反应蛋白(CRP)水平在阿纳金拉治疗前平均为(196 ± 67.8)毫克/升,治疗后平均为(2.6 ± 3.15)毫克/升:总之,这项研究为白细胞介素-1抑制剂(如anakinra)的疗效提供了更多证据,对于常规治疗无效的IRP病例,anakinra是一种很有前景的治疗方式。
{"title":"Anakinra in idiopathic recurrent pericarditis: a comprehensive case series and literature review.","authors":"Zeynep Toker Dincer, Sejla Karup, Erkin Yilmaz, Osman Corbali, Feyza Nur Azman, Melike Melikoglu, Serdal Ugurlu","doi":"10.1007/s00393-023-01471-x","DOIUrl":"10.1007/s00393-023-01471-x","url":null,"abstract":"<p><strong>Objective: </strong>Idiopathic recurrent pericarditis (IRP) is defined by recurring episodes of pericardial inflammation without a known cause. This study investigates the safety and efficacy of anakinra, an interleukin‑1 inhibitor, as a successful therapy for IRP in cases resistant to conventional treatment.</p><p><strong>Methods: </strong>A retrospective evaluation of patients treated at our autoinflammatory center between 2011 and 2023 was conducted. Patient files were examined for demographic, clinical, and treatment response data, including nonsteroid anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine. Monogenic autoinflammatory disease screening was performed for Mediterranean Fever (MEFV), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase (MVK), nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3), and nucleotide-binding oligomerization domain-containing protein 2 (NOD2). Patients who experienced multiple episodes of pericarditis were diagnosed with recurrent pericarditis. The study evaluated anakinra treatment in IRP patients unresponsive to conventional therapy.</p><p><strong>Results: </strong>The study included 21 participants, 9 (42.9%) female and 12 (57.1%) male. The average age of the participants was 43.1 ± 16.5 years. The MEFV mutation analysis revealed that 2 (9.5%) had a mutation in exon 10 and 4 (19.0%) had one in exon 2. Out of the 16 cases, 15 successfully discontinued steroid treatment. Four patients (19.0%) experienced injection site reactions. C‑reactive protein (CRP) levels were measured at an average of 196 ± 67.8 mg/l before and 2.6 ± 3.15 mg/l after anakinra treatment.</p><p><strong>Conclusion: </strong>In conclusion, the study adds to the growing evidence for the efficacy of interleukin-1 inhibitors, such as anakinra, as a promising treatment modality for IRP in cases resistant to conventional treatment.</p>","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139564724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Rheumatology in Germany in the SARS-CoV-2 pandemic]. [SARS-CoV-2大流行期间德国的风湿病学]。
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-30 DOI: 10.1007/s00393-024-01573-0
Hans-Iko Huppertz, Ulf Müller-Ladner, Christof Specker
{"title":"[Rheumatology in Germany in the SARS-CoV-2 pandemic].","authors":"Hans-Iko Huppertz, Ulf Müller-Ladner, Christof Specker","doi":"10.1007/s00393-024-01573-0","DOIUrl":"https://doi.org/10.1007/s00393-024-01573-0","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The German Society for Rheumatology and Clinical Immunology (DGRh) and the COVID-19 pandemic]. [德国风湿病学和临床免疫学学会(DGRh)与 COVID-19 大流行病]。
IF 0.9 4区 医学 Q4 RHEUMATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1007/s00393-024-01540-9
Anna Julia Voormann, Christof Specker

The pandemic led to a global disruption of public life unprecedented in modern times due to an infectious disease, which certainly caused additional special burdens for patients with chronic diseases as well as for personnel in the healthcare system. The German Society of Rheumatology and Clinical Immunology (DGRh), with its Executive Board and two ad hoc commissions, responded promptly to the complex challenges posed by the pandemic for rheumatological care in Germany with provision of a comprehensive and professionally sound range of information and provided concrete assistance in many situations. The diverse activities of the DGRh in the context of the pandemic led to national and international attention and consideration of its committees and recommendations in national committees and guidelines.

大流行病导致全球公共生活因传染病而陷入混乱,这在现代社会是前所未有的,当然也给慢性病患者和医疗系统的工作人员造成了额外的特殊负担。德国风湿病学和临床免疫学会(DGRh)及其执行委员会和两个特设委员会迅速应对了大流行病给德国风湿病治疗带来的复杂挑战,提供了全面和专业的信息,并在许多情况下提供了具体的帮助。德国风湿病研究中心在大流行病背景下开展的各种活动引起了国家和国际的关注,其委员会和建议在国家委员会和指导方针中得到了考虑。
{"title":"[The German Society for Rheumatology and Clinical Immunology (DGRh) and the COVID-19 pandemic].","authors":"Anna Julia Voormann, Christof Specker","doi":"10.1007/s00393-024-01540-9","DOIUrl":"10.1007/s00393-024-01540-9","url":null,"abstract":"<p><p>The pandemic led to a global disruption of public life unprecedented in modern times due to an infectious disease, which certainly caused additional special burdens for patients with chronic diseases as well as for personnel in the healthcare system. The German Society of Rheumatology and Clinical Immunology (DGRh), with its Executive Board and two ad hoc commissions, responded promptly to the complex challenges posed by the pandemic for rheumatological care in Germany with provision of a comprehensive and professionally sound range of information and provided concrete assistance in many situations. The diverse activities of the DGRh in the context of the pandemic led to national and international attention and consideration of its committees and recommendations in national committees and guidelines.</p>","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Zeitschrift fur Rheumatologie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1